Stock Research Report for Panacea Biotec Ltd

Stock score of Panacea Biotec Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Panacea Biotec Ltd by subscribing to ETPrime.

Stock Reports Plus

Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you

*As per competitive benchmarking of annual price. T&C apply

FEATURES & BENEFITS
What you get with Stock Reports Plus?
  • Make Investment decisions

    with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum

  • Find new Trading ideas

    with weekly updated scores and analysts forecasts on key data points

  • In-Depth analysis

    of company and its peers through independent research, ratings, and market data

Login to View Sample Report
Sandeep, now enjoy Stock Reports Plus worth ₹ 1,499*
offered complimentary with your ETPrime membership

*As per competitive benchmarking of annual price. T&C apply

About PANACEABIO

Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.

Frequently Asked Questions
The Economic Times